Gilead Sciences: Liver Cirrhosis, Biliary trials
The registry lists 10 Liver Cirrhosis, Biliary studies with Gilead Sciences as lead sponsor. 2 are open to participants now and 6 have results posted.
Phase 1 1Phase 2 4Phase 3 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of Seladelpar and Cilofexor in Participants With Primary Biliary CholangitisNot yet recruitingNCT07841977Phase 2
- Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisRecruitingNCT06051617Phase 3
- An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)CompletedNCT04950764Phase 1Results posted
- RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)CompletedNCT04620733Phase 3Results posted
- ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)CompletedNCT03602560Phase 3Results posted
- Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)CompletedNCT02955602Phase 2Results posted
- Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without CirrhosisTerminatedNCT02943447Phase 2Results posted
- Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)TerminatedNCT02609048Phase 2Results posted
- Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)CompletedNCT06060665Phase 3
- Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)Active, not recruitingNCT03301506Phase 3